Apremilast

Apremilast (CC-10004) is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC50 of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC50 of 104 nM[1].

Product Specifications

CAS Number

[608141-41-9]

Product Name Alternative

CC-10004

UNSPSC

12352005

Hazard Statement

H302, H312, H332, H361, H372

Target

Apoptosis; Phosphodiesterase (PDE) ; TNF Receptor

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Apremilast.html

Purity

99.91

Solubility

DMSO : 44 mg/mL (ultrasonic)

Smiles

CC(NC1=CC=CC(C(N2[C@@H](C3=CC=C(OC)C(OCC)=C3)CS(=O)(C)=O)=O)=C1C2=O)=O

Molecular Formula

C22H24N2O7S

Molecular Weight

460.50

Precautions

H302, H312, H332, H361, H372

References & Citations

[1]Perez-Aso M, et al. Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. Arthritis Res Ther. 2015 Sep 15;17:249.|[2]Chen LG, et al. Determination of Apremilast in Rat Plasma by UPLC-MS-MS and Its Application to a Pharmacokinetic Study. J Chromatogr Sci. 2016 Sep;54 (8) :1336-40.